Alnylam has said it will not proceed with a clinical trial of its RNAi drug vutrisiran in the rare eye disorder Stargardt disease – at least for now – tying its decision to President Joe Biden ...
But this year the company is working on launching an exciting new therapy for a rare eye disease and is stretching into the US market for their planned launch. At the conference, editor-in-chief ...
News on rare diseases, including the development of new treatments, the challenges of diagnosis and treatment and the stories of patients and their families. The page features in-depth reporting ...